Loss of the fructose transporter SLC2A5 inhibits cancer cell migration.
cancer
cell migration
invadopodia
metastasis
mitochondria
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
03
2022
accepted:
09
09
2022
entrez:
21
10
2022
pubmed:
22
10
2022
medline:
22
10
2022
Statut:
epublish
Résumé
Metastasis is the primary cause of cancer patient death and the elevation of SLC2A5 gene expression is often observed in metastatic cancer cells. Here we evaluated the importance of SLC2A5 in cancer cell motility by silencing its gene. We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration
Identifiants
pubmed: 36268513
doi: 10.3389/fcell.2022.896297
pii: 896297
pmc: PMC9578049
doi:
Types de publication
Journal Article
Langues
eng
Pagination
896297Informations de copyright
Copyright © 2022 Groenendyk, Stoletov, Paskevicius, Li, Dai, Pujol, Busaan, Ng, Boukouris, Saleme, Haromy, Cui, Hu, Yan, Zhang, Michelakis, Chen, Lewis, Tang, Agellon and Michalak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Signal. 2014 Jun 10;7(329):ra54
pubmed: 24917591
Oncotarget. 2015 Jan 1;6(1):570-83
pubmed: 25402435
Methods Mol Biol. 2016;1458:27-37
pubmed: 27581012
J Vis Exp. 2014 Oct 27;(92):e51998
pubmed: 25408172
Biophys J. 2013 May 7;104(9):2077-88
pubmed: 23663851
Oncogene. 2013 Oct;32(40):4814-24
pubmed: 23128392
J Cell Sci. 2010 Jul 1;123(Pt 13):2332-41
pubmed: 20530574
Nat Commun. 2018 Jun 14;9(1):2343
pubmed: 29904055
Br J Cancer. 2021 Aug;125(5):734-747
pubmed: 34188196
Nature. 2015 Oct 15;526(7573):397-401
pubmed: 26416735
J Mol Biol. 2008 May 2;378(3):530-9
pubmed: 18387633
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Cell Death Dis. 2018 May 10;9(5):557
pubmed: 29748554
Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52
pubmed: 8700847
Cancer Metab. 2021 Mar 24;9(1):12
pubmed: 33762003
Trends Cell Biol. 2018 Oct;28(10):823-834
pubmed: 29970282
Liver Int. 2018 Jul;38(7):1263-1272
pubmed: 29210177
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
Cell Adh Migr. 2013 Sep-Oct;7(5):395-403
pubmed: 24131935
Cells. 2018 Jun 02;7(6):
pubmed: 29865240
Mol Cell Biol. 2001 Sep;21(17):5846-56
pubmed: 11486024
EMBO Rep. 2011 Oct 28;12(11):1182-8
pubmed: 21941299
J Biol Chem. 2014 Jan 24;289(4):2230-49
pubmed: 24302731
Cell Metab. 2018 Jun 05;27(6):1249-1262.e4
pubmed: 29706565
Int J Cancer. 1977 Jan;19(1):128-35
pubmed: 832918
Cancer Rep (Hoboken). 2020 Feb;3(1):e1157
pubmed: 32671955
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17406-11
pubmed: 17954920
PLoS One. 2013 Oct 09;8(10):e76899
pubmed: 24130806
Nutrients. 2017 Sep 06;9(9):
pubmed: 28878197
JCI Insight. 2020 Feb 13;5(3):
pubmed: 32051337
FASEB J. 2018 Sep;32(9):5104-5118
pubmed: 29913554
Cancer Cell. 2016 Nov 14;30(5):779-791
pubmed: 27746145
Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E227-37
pubmed: 18398011
Cell Mol Life Sci. 2017 Jun;74(11):1999-2017
pubmed: 28083595
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
Mol Biol Cell. 2017 Aug 1;28(16):2159-2169
pubmed: 28615318
Mol Biol Cell. 2002 Dec;13(12):4343-54
pubmed: 12475957
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43
pubmed: 26124089
Metabolism. 2014 Jul;63(7):895-902
pubmed: 24814684
Nat Med. 2006 Aug;12(8):895-904
pubmed: 16892035
Expert Rev Anticancer Ther. 2015;15(7):733-5
pubmed: 26098830
Cancer. 1974 Apr;33(4):1027-33
pubmed: 4132053
Onco Targets Ther. 2019 Jul 08;12:5425-5436
pubmed: 31371983
Pflugers Arch. 2004 Feb;447(5):480-9
pubmed: 12750891
Front Cell Dev Biol. 2019 Dec 20;7:355
pubmed: 31921862
Cell Rep. 2014 Sep 11;8(5):1558-70
pubmed: 25176655
Biol Rev Camb Philos Soc. 2015 Aug;90(3):927-63
pubmed: 25243985